Australian Paediatric Surveillance Unit

Severe Complications of Influenza in Children <16 Years and admitted to hospital (1st May 2024 to 30th September 2024)
Additional case report forms can be downloaded from www.apsu.org.au

Instructions: Please answer each question by ticking the appropriate box or writing your response in the space provided. DK= Don't Know

REPORTING CLINICIANS DETAILS:							
1. Dr Name:	Ph:	Email:	Email:				
2. Hospital:		APSU code (if know	vn):				
3. Date questionnaire completed	://						
PATIENT DETAILS:							
4. First 2 letters of first name:		5. First 2 letters of s	surname:				
6. Date of Birth:	//	7. Sex:	□м □ғ				
8. Postcode of family:		9. Country of Birth:	☐ Australia ☐ Other <i>(specify):</i> ☐ DK				
10. Ethnicity:	☐ Aboriginal ☐ Torres Strait Islander ☐ Both Aboriginal and To Strait Islander	☐ Caucasian ☐ Asian Pacific Islander ☐ Middle Eastern	☐ African ☐ Other <i>(specify)</i> ☐ DK				
SECTION A: Diagnosis, Presentatio	n and Treatment						
11. Date of onset of symptoms:	/	/					
12. Date of 1 st admission to hospi	tal:/	/					
13. Admitted to ICU?	□Yes□	l _{No} □ _{DK}					
<i>If yes,</i> specify date of admission:	on to ICU:/	/ days					
14. How was influenza confirmed	? DNose swab		aspirate Other (specify):				
15. Which lab tests were +ve for i		r - / O	Serology Rapid Antigen Test				
16. Results: Influenza type?			a service y and antigen rest				
17. Was further sub-typing done?		Ino □dk					
If Yes, which sub-type was pre (e.g. H1N1, H3N2, H5N1)							
18. Which of the following symptowere apparent on presentation to hospital? Fever	Pneumor Acute Re Encepha Cerebrov Seizure (s Myocard Rhabdon Purpura Hepatitis Guillain-I Shock (re Acute kid Reye Syn Cher (sp Laborato	fulminans Disseminated Pancreatitis se myelitis Polyneuritis Barré syndrome equiring fluid resuscitation) dney injury drome pecify): pry proven bacterial co-infect	(ARDS) Ingoencephalitis Cardiomyopathy Cardiac failure I intravascular coagulopathy Liver failure Mononeuritis Acute disseminated encephalomyelitis Stage 1 2 3 (refer to study info sheet) tion; specify organism and site of infection: specify organism and site of infection:				
		y proven covid-13 co-me	CUOTI				

20. Was respiratory support required?	□Yes	□No	□dk			
<i>If yes,</i> please indicate:	□ Non-ir	n therapy onvasive vento ve ventilation orporeal M	tilation (e	e.g., CPAP) Oxygenation (ECMO)	
Duration? (days):				days		
21a) Was the child treated with:	☐ Zanam ☐ Neithe	nivir (Relenz er	:a) Dat	e commenced: e commenced:	//	d://
b)	☐Antibi	otics	If Yes,	, which ones?		
c)	☐ Aspirir	า	□ IV F	luids		
SECTION B: Underlying medical conditions an	d history					
22. Is the child immunocompromised (e.g. HIV +ve, primary immunodeficiency, treated for malignancy)?	□Yes	□No	□dk			
<i>If yes,</i> specify:						
23. Has the child any other chronic illness that might increase the risk of influenza complications?	□Yes	□No	□dk			
<i>If yes,</i> which one(s)?	☐ Neuro ☐ Asthm ☐ Other ☐ Prema ☐ Cerebi	nital heart of muscular di la chronic lun lturity ral Palsy	isorder g disease	e, specify:		
24. Did the child receive the Flu vaccine in the last 12 months?	□Yes	□No	□dk			
If yes, when? If yes, which vaccine?	/_	_/	□dk			🗆 дк
25. Has the child been vaccinated against pneumococcus?	□Yes	□No	□dk			
If yes, when?	/_	/	□dk			
26. Prior to admission did the child have contact with a person with laboratory confirmed influenza?	□Yes	□No	□dk			
<i>If yes,</i> what was the relationship to the child? (e.g. parent, sibling, friend):						DK
If yes, was the contact person a:	Child	☐ Adult	Age of	contact if known:		DK
27. Did the child travel overseas in the 7 days before onset of symptoms?	□Yes	□No	□dk			_
If yes, where?						DK
28. Has the child visited a farm/business in the past 7 days?	□Yes	□No	□dk			
<i>If yes,</i> was it:	☐ Comm	ercial live p	oultry	\square Pig handling	□dk	
SECTION C: COVID-19						
29. Has the child had PREVIOUS infection with COVID-19?	□Yes	□No	□dk			
If yes, when: If yes, were they admitted to hospital?	 □ Yes	(month) _.	□DK	(year)		

If yes, did they require respiratory support?	□Yes	□No	□dk					
Please list any other complications of COVID-19 infection:								□ dk
30. How many doses of COVID-19 vaccine has the child received?	□о	□1	□ 2	□ 3	□ DK			
SECTION D: Outcome								
31 . At the time of reporting, was the child:	☐ In ICU	□ Hos	pitalised	□ Disch	arged Alive	☐ Died	□ dk	
32 . Date of Discharge:	/	/_						
33. Were there any ongoing problems on discharge?	□Yes	□No	□dk					
If yes, specify:								
34. If died, date of death:	/	/_						
Was a cause of death determined?	□Yes	□No	□dk					
If yes, specify:								

If the child is still in ICU or hospital at the time of this report we will contact you in one month to see if the child has been discharged well or with problems or has died.

Please return this case report form ASAP by email to SCHN-APSU@health.nsw.gov.au or via FAX: (02) 9845 3082

Thank you for your help with this research project.

Please return this case report form to the APSU via email to <u>SCHN-APSU@health.nsw.gov.au</u> or by mail to: Australian Paediatric Surveillance Unit, Kids Research, Locked Bag 4001, Westmead NSW 2145

The APSU is affiliated with the Royal Australasian College of Physicians (Paediatrics and Child Health Division) and Faculty of Medicine and Health, The University of Sydney.

The APSU is funded by the Australian Government Department of Health and Aged Care.

All research in Australia involving humans is reviewed by an independent group of people called a Human Research Ethics Committee (HREC).

This study has been approved by the Sydney Children's Hospitals Network (SCHN) HREC (approval number: 2020/ETH03310).

If you have any concerns or complaints about any aspect of the project or the way it is being conducted, you may contact the Executive Officer of the SCHN HREC on (02) 7825 1253 or SCHN-Ethics@health.nsw.gov.au.